Type Fab fragment Target CFD ATC code none | Source Humanized (from mouse) Routes of
administration Intravitreal | |
Legal status Phase 3 clinical trials | ||
Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody designed for the treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration. It binds to complement factor D (CFD).
Enrollment in Phase 3 clinical trials was initiated in 2014. Phase 3 trials are usually conducted in order to establish the effectiveness of a drug, and compare the results to known alternative treatments.
References
Lampalizumab Wikipedia(Text) CC BY-SA